JP2016531924A5 - - Google Patents

Download PDF

Info

Publication number
JP2016531924A5
JP2016531924A5 JP2016540383A JP2016540383A JP2016531924A5 JP 2016531924 A5 JP2016531924 A5 JP 2016531924A5 JP 2016540383 A JP2016540383 A JP 2016540383A JP 2016540383 A JP2016540383 A JP 2016540383A JP 2016531924 A5 JP2016531924 A5 JP 2016531924A5
Authority
JP
Japan
Prior art keywords
binding
heavy chain
binding molecule
igm
chain constant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016540383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531924A (ja
JP6721505B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/054079 external-priority patent/WO2015053887A1/en
Publication of JP2016531924A publication Critical patent/JP2016531924A/ja
Publication of JP2016531924A5 publication Critical patent/JP2016531924A5/ja
Application granted granted Critical
Publication of JP6721505B2 publication Critical patent/JP6721505B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016540383A 2013-09-05 2014-09-04 定常領域が修飾された(constant chain modified)二重特異性五価及び六価Ig−M抗体 Expired - Fee Related JP6721505B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361874284P 2013-09-05 2013-09-05
US201361874277P 2013-09-05 2013-09-05
US61/874,284 2013-09-05
US61/874,277 2013-09-05
PCT/US2014/054079 WO2015053887A1 (en) 2013-09-05 2014-09-04 Constant chain modified bispecific, penta- and hexavalent ig-m antibodies

Publications (3)

Publication Number Publication Date
JP2016531924A JP2016531924A (ja) 2016-10-13
JP2016531924A5 true JP2016531924A5 (enExample) 2017-10-12
JP6721505B2 JP6721505B2 (ja) 2020-07-15

Family

ID=51542496

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016540383A Expired - Fee Related JP6721505B2 (ja) 2013-09-05 2014-09-04 定常領域が修飾された(constant chain modified)二重特異性五価及び六価Ig−M抗体

Country Status (9)

Country Link
US (1) US10351631B2 (enExample)
EP (1) EP3041862B1 (enExample)
JP (1) JP6721505B2 (enExample)
KR (1) KR102306492B1 (enExample)
CN (1) CN105722855B (enExample)
AU (1) AU2014332458B2 (enExample)
CA (1) CA2922830A1 (enExample)
DK (1) DK3041862T3 (enExample)
WO (1) WO2015053887A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP5764677B2 (ja) 2011-02-28 2015-08-19 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合タンパク質
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
RU2016115866A (ru) * 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
CA2944647C (en) 2014-04-03 2025-07-08 Igm Biosciences Inc MODIFIED J STRING
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
IL297997A (en) * 2015-03-04 2023-01-01 Igm Biosciences Inc Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CA2983034A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
HUE069387T2 (hu) 2015-09-30 2025-03-28 Igm Biosciences Inc Módosított J-lánccal rendelkezõ kötõmolekulák
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
US11401337B2 (en) 2017-04-07 2022-08-02 Igm Biosciences, Inc. Modified human IgM constant regions for modulation of complement-dependent cytolysis effector function
CN111787951B (zh) 2018-03-01 2025-06-17 Igm生物科学股份有限公司 影响IgM血清半衰期的IgM Fc和J链突变
EP4013792A4 (en) 2019-08-15 2023-10-04 IGM Biosciences Inc. IMMUNO-STIMULATING MULTIMER BINDING MOLECULES
IL297029A (en) 2020-04-22 2022-12-01 Igm Biosciences Inc Multimeric binding compounds as pd-1 agonists
CA3245061A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines Inc T-CELL RECEIVER MULTIMERS AND THEIR USES
JP2025532897A (ja) * 2022-09-28 2025-10-03 ドレン バイオ, インコーポレイテッド 多重特異性抗体及びその使用方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK1626992T3 (da) 2003-05-23 2010-09-20 Crucell Holland Bv Produktion af rekombinant IgM i PER.C6-celler
WO2006008548A2 (en) * 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
JP2008519030A (ja) 2004-11-05 2008-06-05 パリンゲン インコーポレーテッド 抗体で誘導される細胞膜損傷
US8349332B2 (en) * 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
PT2235064E (pt) * 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
US9676845B2 (en) * 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US20130129723A1 (en) * 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
WO2013049254A1 (en) * 2011-09-26 2013-04-04 Jn Biosciences Llc Hybrid constant regions
PL2794905T3 (pl) * 2011-12-20 2020-11-02 Medimmune, Llc Zmodyfikowane polipeptydy dla rusztowań przeciwciał dwuswoistych
MX363819B (es) 2012-02-08 2019-04-03 Igm Biosciences Inc Uniones a cdim y sus usos.
AU2015206002B2 (en) 2014-01-16 2020-06-11 Mario Umberto Francesco MONDELLI Neutralizing human monoclonal antibodies against Hepatitis B Virus surface antigen
WO2015120474A1 (en) 2014-02-10 2015-08-13 Igm Biosciences, Inc. Iga multi-specific binding molecules
CA2944647C (en) 2014-04-03 2025-07-08 Igm Biosciences Inc MODIFIED J STRING
US10689449B2 (en) 2015-01-20 2020-06-23 Igm Biosciences, Inc. Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof
IL297997A (en) 2015-03-04 2023-01-01 Igm Biosciences Inc Cd20 binding molecules and uses thereof
WO2016154593A1 (en) 2015-03-25 2016-09-29 Igm Biosciences, Inc. Multi-valent hepatitis b virus antigen binding molecules and uses thereof
CA2983034A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
US11639389B2 (en) 2015-09-30 2023-05-02 Igm Biosciences, Inc. Binding molecules with modified J-chain
HUE069387T2 (hu) 2015-09-30 2025-03-28 Igm Biosciences Inc Módosított J-lánccal rendelkezõ kötõmolekulák
WO2017196867A1 (en) 2016-05-09 2017-11-16 Igm Biosciences, Inc. Anti-pd-l1 antibodies
CN109561681A (zh) 2016-07-20 2019-04-02 Igm生物科学股份有限公司 多聚gitr结合分子及其用途
AU2017299610B2 (en) 2016-07-20 2022-09-29 Igm Biosciences, Inc. Multimeric CD40 binding molecules and uses thereof
CA3030647A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric ox40 binding molecules and uses thereof
WO2018017761A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof

Similar Documents

Publication Publication Date Title
JP2016531924A5 (enExample)
ES2885815T3 (es) Nuevo formato biespecífico adecuado para su uso en el cribado de alto rendimiento
JP2014518883A5 (enExample)
US11286312B2 (en) Multispecific antibodies
JP2019500862A5 (enExample)
JP2018502572A5 (enExample)
JP2018537415A5 (enExample)
JP2017114866A5 (enExample)
JP2017529067A5 (enExample)
Maaß et al. Cystine‐knot peptides targeting cancer‐relevant human cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4)
JP2019526273A5 (enExample)
JP2020517287A5 (enExample)
JP2017511130A5 (enExample)
JP2014158485A5 (enExample)
JP2016536322A5 (enExample)
HRP20201517T1 (hr) Anti-cd3 protutijela, anti-cd123 protutijela i bispecifična protutijela koja se specifično vežu na cd3 i/ili cd123
JP2019522490A5 (enExample)
JP2016533174A5 (enExample)
FI4050034T3 (fi) Cd3:een sitoutuvia vasta-aineita
JP2018516554A5 (enExample)
JP2017504578A5 (enExample)
WO2009132020A3 (en) Selective high-affinity polydentate ligands and methods of making such
JP2020500510A5 (enExample)
JP2014527408A5 (enExample)
RU2015152077A (ru) Тримерные антигенсвязывающие молекулы